Eastman Chemical stock price target lowered to $74 at RBC Capital

Published 05/08/2025, 17:48
Eastman Chemical stock price target lowered to $74 at RBC Capital

Investing.com - RBC Capital has lowered its price target on Eastman Chemical (NYSE:EMN) to $74.00 from $91.00 while maintaining an Outperform rating on the stock. According to InvestingPro data, the stock appears undervalued, trading at an attractive P/E ratio of 8.6x with a dividend yield of 5.46%.

The price target reduction follows Eastman Chemical’s second-quarter earnings miss and lower third-quarter guidance, with the company projecting $1.25 in earnings per share for Q3 compared to $1.60 in Q2, primarily due to inventory destocking. InvestingPro data shows 12 analysts have recently revised their earnings expectations downward, though the company maintains strong fundamentals with a 32-year track record of consistent dividend payments.

Despite near-term challenges, RBC Capital believes next year will likely see a "material step-up" in performance based on several factors, including abating utilization headwinds of approximately $75-100 million in the second half of 2025.

The firm also cited the full-year contribution of Eastman’s approximately $75 million cost-reduction plan, potential additional cost reductions in 2026, and full-year contribution from ramped capacity as positive factors for future performance.

RBC Capital has reduced its EBITDA estimates for Eastman Chemical to $355 million for Q3, $1.545 billion for fiscal year 2025, and $1.70 billion for fiscal year 2026, down from previous estimates of $460 million, $1.725 billion, and $1.85 billion respectively.

In other recent news, Eastman Chemical Company reported its Q2 2025 earnings, which fell short of expectations. The company posted earnings per share of $1.60, missing the forecasted $1.73. Additionally, revenue came in at $2.29 billion, slightly below the anticipated $2.30 billion. In another development, KeyBanc Capital Markets adjusted its outlook on Eastman Chemical by lowering its price target to $79 from $93. Despite the adjustment, KeyBanc maintained an Overweight rating on the stock. The firm cited demand uncertainty as a significant factor, leading to an 18% reduction in its 2025 earnings per share estimate. These developments highlight recent challenges and adjustments faced by Eastman Chemical.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.